Trastuzumab deruxtecan

DRUG NAME: Trastuzumab deruxtecan trastuzumab CONCLUSION: Administering higher doses on a 3-weekly schedule did not compromise the efficacy and safety of trastuzumab in women with HER2-positive MBC, and trastuzumab trastuzumab emtansine continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients

trastuzumab trastuzumab A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2